MA37830B1 - Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk) - Google Patents

Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)

Info

Publication number
MA37830B1
MA37830B1 MA37830A MA37830A MA37830B1 MA 37830 B1 MA37830 B1 MA 37830B1 MA 37830 A MA37830 A MA 37830A MA 37830 A MA37830 A MA 37830A MA 37830 B1 MA37830 B1 MA 37830B1
Authority
MA
Morocco
Prior art keywords
compounds
heteroromatic
btk
inhibitors
tyrosine kinase
Prior art date
Application number
MA37830A
Other languages
English (en)
Other versions
MA20150290A1 (fr
Inventor
Joerg Martin Bentzien
Angela Kay Berry
Todd Bosanac
Michael Burke
Darren Disalvo
Joshua Horan
Shuang Liang
Can Mao
Wang Mao
Yue Shen
Fariba Soleymanzadeh
Renee Zindell
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49029216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37830(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA20150290A1 publication Critical patent/MA20150290A1/fr
Publication of MA37830B1 publication Critical patent/MA37830B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La présente invention concerne des composé de formule (i) où les groupes a, cy, xi et y sont définis ici, qui sont appropriés pour le traitement d'une maladie choisie parmi la polyarthrite rhumatoïde, le lupus érythromateux disséminé, la sclérodermie, l'asthme, la rhinite allergique, l'eczéma allergique, le lymphome à cellules b, la sclérose en plaques, la polyarthrite rhumatoïde juvénile, l'arthrite idiopathique juvénile, la maladie intestinale inflammatoire, la maladie du greffon contre l'hôte, l'arthrite psoriasique, la spondylarthrite ankylosante et l'uvéite.
MA37830A 2012-08-10 2013-08-08 Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk) MA37830B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681684P 2012-08-10 2012-08-10
PCT/US2013/054096 WO2014025976A1 (fr) 2012-08-10 2013-08-08 Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)

Publications (2)

Publication Number Publication Date
MA20150290A1 MA20150290A1 (fr) 2015-08-31
MA37830B1 true MA37830B1 (fr) 2018-09-28

Family

ID=49029216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37830A MA37830B1 (fr) 2012-08-10 2013-08-08 Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)

Country Status (24)

Country Link
US (5) US20140045813A1 (fr)
EP (1) EP2882741B1 (fr)
JP (1) JP6348492B2 (fr)
KR (1) KR20150040292A (fr)
CN (1) CN104603124B (fr)
AP (1) AP2015008203A0 (fr)
AU (1) AU2013299557B2 (fr)
BR (1) BR112015002590A2 (fr)
CA (1) CA2881519A1 (fr)
CL (1) CL2015000256A1 (fr)
EA (1) EA029210B1 (fr)
EC (1) ECSP15008851A (fr)
GE (1) GEP201706748B (fr)
IL (1) IL236495A0 (fr)
IN (1) IN2015DN00524A (fr)
MA (1) MA37830B1 (fr)
MX (1) MX2015001802A (fr)
NZ (1) NZ703607A (fr)
PE (1) PE20150756A1 (fr)
PH (1) PH12015500294A1 (fr)
SA (1) SA515360007B1 (fr)
SG (1) SG11201500499TA (fr)
TN (1) TN2015000029A1 (fr)
WO (1) WO2014025976A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
CN105008344B (zh) * 2012-11-02 2017-07-25 辉瑞公司 布鲁顿氏酪氨酸激酶抑制剂
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
JP6403751B2 (ja) 2013-03-14 2018-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ５−チアゾールカルボキサミン誘導体及びｂｔｋ阻害剤としてのその使用
EP2970300B1 (fr) 2013-03-15 2018-05-16 Boehringer Ingelheim International GmbH Composés hétéroaromatiques en tant qu'inhibiteurs btk
ES2924193T3 (es) * 2013-03-15 2022-10-05 Janssen Pharmaceutica Nv Procesos e intermedios para preparar un medicamento
RS60934B1 (sr) 2013-09-30 2020-11-30 Guangzhou Innocare Pharma Tech Co Ltd Supstituisani nikotinimidni inhibitori btk i njihova priprema i upotreba u lečenju karcinoma, inflamatorne i autoimune bolesti
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
US9828364B2 (en) * 2014-01-29 2017-11-28 Boehringer Ingelheim International Gmbh Pyrazole compounds as BTK inhibitors
WO2015185998A2 (fr) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
ES2828431T3 (es) * 2015-12-16 2021-05-26 Loxo Oncology Inc Compuestos útiles como inhibidores de cinasa
PE20181074A1 (es) * 2015-12-16 2018-07-04 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk
CN105646318A (zh) * 2015-12-30 2016-06-08 武汉药明康德新药开发有限公司 一种2-叔丁氧羰基-5-氮杂螺环[3.3]庚烷-6-羧酸的合成方法
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
CN107226805A (zh) * 2016-03-24 2017-10-03 北京天诚医药科技有限公司 芳香族酰胺类衍生物、其制备方法及其在医药上的应用
RS64541B1 (sr) 2016-08-15 2023-09-29 Novartis Ag Režimi i postupci za lečenje multiple skleroze upotrebom ofatumumaba
CN107759602B (zh) * 2016-08-17 2020-04-21 中国科学院上海药物研究所 含有共轭联烯结构的化合物、其药物组合物和用途
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
JP7166331B2 (ja) 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EP3886854A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2020120673A1 (fr) 2018-12-13 2020-06-18 Intervet International B.V. Procédé de préparation de 1-[(3r,4s)-4-cyanotétrahydropyran-3-yl]-3-[(2-fluoro-6-méthoxy-4-pyridyl)amino]pyrazole-4-carboxamide
KR102200032B1 (ko) * 2019-03-13 2021-01-08 전남대학교산학협력단 호흡기 질환의 예방 또는 치료용 조성물
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
WO2020228637A1 (fr) 2019-05-10 2020-11-19 Henan Normal University 1-amino-1h-imidazole-5-carboxamide substitué utilisé en tant qu'inhibiteurs de la tyrosine kinase de bruton
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
MX2023000150A (es) 2020-06-19 2023-03-22 Anaxis Pharma Pty Ltd Compuesto de sulfonamida.
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用
WO2023110936A1 (fr) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Inhibiteurs de kinase réversibles macrocycliques
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제
CN116554102B (zh) * 2022-01-28 2025-10-03 深圳海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法和应用
TW202416955A (zh) * 2022-08-04 2024-05-01 英商海普泰爾思治療公司 毒蕈鹼受體激動劑

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
WO2003015776A1 (fr) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Derives de thiazolyl 2,4,5-trisubstitue et activite anti-inflammatoire associee
EP1436265A4 (fr) 2001-09-27 2004-12-15 Smithkline Beecham Corp Composes chimiques
FR2881426B1 (fr) * 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
US7589214B2 (en) * 2006-04-11 2009-09-15 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
EP2297142B1 (fr) 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Nouvelles pyridine-2-ones et pyridazine-3-ones substituées
WO2010012690A1 (fr) 2008-07-29 2010-02-04 Université de Liège Essai de marqueur génétique pour le brachyspina et la fertilité chez les bovins
GB0820819D0 (en) * 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AU2010341229A1 (en) 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
MX2012013622A (es) 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
EP2603216A4 (fr) * 2010-08-11 2013-12-18 Millennium Pharm Inc Hétéroaryles et utilisations
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
JP5859640B2 (ja) 2011-05-17 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ阻害剤
HK1197060A1 (en) 2011-08-17 2015-01-02 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104080789B (zh) 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2013157022A1 (fr) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Composés hétéro-bicycliques substitués, compositions et leurs applications médicinales
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
CA2881761A1 (fr) 2012-09-13 2014-03-20 Christine E. Brotherton-Pleiss Inhibiteurs de la tyrosine kinase de bruton
CN105008344B (zh) 2012-11-02 2017-07-25 辉瑞公司 布鲁顿氏酪氨酸激酶抑制剂
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
EP2970300B1 (fr) 2013-03-15 2018-05-16 Boehringer Ingelheim International GmbH Composés hétéroaromatiques en tant qu'inhibiteurs btk
EP3042899A1 (fr) 2013-09-03 2016-07-13 Carna Biosciences Inc. Dérivé de 2,6-diaminopyrimidine d'un nouveau type
US9828364B2 (en) 2014-01-29 2017-11-28 Boehringer Ingelheim International Gmbh Pyrazole compounds as BTK inhibitors
PE20181074A1 (es) 2015-12-16 2018-07-04 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk

Also Published As

Publication number Publication date
EA201500207A1 (ru) 2015-08-31
NZ703607A (en) 2018-02-23
SG11201500499TA (en) 2015-03-30
EP2882741A1 (fr) 2015-06-17
US20180086748A1 (en) 2018-03-29
TN2015000029A1 (en) 2016-06-29
IN2015DN00524A (fr) 2015-06-26
HK1210161A1 (en) 2016-04-15
AU2013299557A1 (en) 2015-01-29
JP2015524480A (ja) 2015-08-24
US20190112302A1 (en) 2019-04-18
JP6348492B2 (ja) 2018-06-27
ECSP15008851A (es) 2015-12-31
SA515360007B1 (ar) 2016-09-04
US10138229B2 (en) 2018-11-27
IL236495A0 (en) 2015-02-26
US20160031872A1 (en) 2016-02-04
MX2015001802A (es) 2015-05-07
CN104603124A (zh) 2015-05-06
AU2013299557B2 (en) 2017-06-22
CA2881519A1 (fr) 2014-02-13
CN104603124B (zh) 2018-04-17
AP2015008203A0 (en) 2015-01-31
EP2882741B1 (fr) 2018-10-24
MA20150290A1 (fr) 2015-08-31
EA029210B1 (ru) 2018-02-28
PE20150756A1 (es) 2015-06-03
PH12015500294B1 (en) 2015-04-20
US20170320867A1 (en) 2017-11-09
GEP201706748B (en) 2017-10-10
BR112015002590A2 (pt) 2019-08-06
KR20150040292A (ko) 2015-04-14
US10875852B2 (en) 2020-12-29
US20140045813A1 (en) 2014-02-13
CL2015000256A1 (es) 2015-07-03
WO2014025976A1 (fr) 2014-02-13
PH12015500294A1 (en) 2015-04-20

Similar Documents

Publication Publication Date Title
MA20150290A1 (fr) Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
MY155639A (en) 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
EA201492250A1 (ru) Гетероциклическое соединение
MA38080A1 (fr) Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
IN2012CH01573A (fr)
MY196260A (en) Small Molecule Inhibitors of the Jak Family Of Kinases
ECSP088813A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
TN2014000033A1 (fr) Indazoles
EA201290305A1 (ru) Производные трициклического пиразоламина
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
CA2642211A1 (fr) Composes de 2,4-pyrimidinediamine pour le traitement ou la prevention de maladies autoimmunes
MA39193B1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
JP2015535851A5 (fr)
MA38284A1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
NZ617025A (en) (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability
EA202192032A1 (ru) Соединения n-ацил-{4-[(4-арилфенил)сульфонилметил]пиперидина} и их терапевтическое применение
EA201591881A1 (ru) Гетероциклическое соединение
MA38079A1 (fr) Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés
CN112135826A (zh) 氨基降茨烷衍生物及其制备方法与应用
MX2018003008A (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos.
MA41494B1 (fr) Composés benzoxaborole substitués en position 4 et utilisations associées
AU2022283404A1 (en) Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals